Liftoff Mobile Delays IPO Plans for the Time Being
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Should l Buy EIKN?
Source: Barron's
- IPO Postponement: Liftoff Mobile has delayed its initial public offering (IPO) due to unfavorable market conditions.
- Market Impact: The decision follows a day marked by significant declines in stock prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EIKN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EIKN
Wall Street analysts forecast EIKN stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 13.780
Low
Averages
High
Current: 13.780
Low
Averages
High
About EIKN
Eikon Therapeutics, Inc. is a United States-based drug discovery and development company. The Company’s platform allows resolution microscopy as well as the advances in biology, chemistry, engineering, and automation. It tracks and measures the real-time movement of individual proteins in living cells to understanding of disease biology and discover differentiated therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
February IPO Market Review and Outlook
- Strong Fundraising: In February, 13 IPOs raised a total of $4.4 billion, surpassing the historical average over the past decade, indicating sustained investor interest in new listings despite market volatility.
- Market Volatility Impact: Although IPO activity was robust at the beginning of February, concerns over AI disruption led to a sell-off in tech stocks mid-month, resulting in price cuts and postponements for some high-profile IPOs, reflecting market uncertainty.
- Return Performance: The average return for IPOs this month was 22%, with those raising over $100 million achieving an impressive 28%, suggesting that investors remain optimistic about growth potential in the biotech and consumer sectors.
- Optimistic Future Outlook: Despite a decline in new filing activity, stabilizing market conditions are expected to encourage a gradual increase in IPO issuance in March, particularly given the strong performance of recent listings.
See More
Key Wall Street Rating Changes on Monday
- Morgan Stanley Bullish on Nvidia: Morgan Stanley names Nvidia a top pick, viewing the current stock price at 18x CY27 EPS as an attractive entry point, expecting market concerns about growth durability to shift to enthusiasm in the coming months.
- Barclays Downgrades Blue Owl: Barclays downgrades Blue Owl from overweight to equal weight, citing overly high market estimates and suggesting that the stock is now closer to fairly priced based on earnings growth potential.
- Piper Sandler Upgrades CrowdStrike: Piper Sandler upgrades CrowdStrike from neutral to overweight, maintaining a $520 price target, arguing that the market's bearish sentiment driven by AI narratives is overdone for a leading security platform with a strong track record.
- Goldman Sachs Upgrades Dutch Bros: Goldman Sachs upgrades Dutch Bros from neutral to buy, asserting that the market is underestimating the coffee chain's fundamental strength and competitive positioning amid a challenging coffee landscape.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Dynamics Overview: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: For those considering buying NTRP stock, analysts' opinions may provide crucial market insights, aiding in more informed investment choices.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst rating changes, and investors should monitor these shifts to seize market opportunities.
See More
U.S. IPO Market Set for Significant Wave in 2026
- Surge in IPO Proceeds: Goldman Sachs projects that U.S. IPO proceeds will reach a record $160 billion in 2026, quadrupling from 2025, indicating strong economic recovery and robust equity markets.
- Doubling of IPO Count: The number of IPOs is expected to double to 120 in 2026, driven by a recovering economy, rising equity prices, and favorable financial conditions, with software and healthcare sectors leading the charge.
- Large Company Listings: Goldman Sachs notes that 2026 IPOs will be dominated by large private company listings, with proceeds estimated between $80 billion and $200 billion, although recent selloffs in software stocks highlight valuation risks.
- Signs of Market Activity: Approximately $5 billion has already been raised through IPOs in 2026, including notable companies like AI equipment manufacturer Forgent Power and biopharmaceutical firm Eikon Therapeutics, reflecting a strong market rebound.
See More
US IPO Market Set for Major Rebound in 2026
- IPO Revenue Forecast: Goldman Sachs analysts predict that US IPO proceeds will reach a record $160 billion in 2026, quadrupling from 2025, reflecting strong demand for major companies, particularly with anticipated listings from SpaceX and OpenAI.
- Surge in IPO Numbers: The number of IPOs is expected to double to 120 in 2026, driven by economic growth, rising equity prices, and improved financial conditions, indicating strong market interest and confidence in new public offerings.
- Industry Dominance: Software and healthcare firms are set to dominate the IPO pipeline by volume, while late-stage tech and AI companies are expected to drive proceeds, showcasing ongoing investor focus and trust in technological innovation.
- Market Risk Warning: Despite the optimistic outlook, Goldman warns that ongoing volatility in software stocks and lack of corporate confidence could impact the IPO market, particularly as the software sector accounts for about a quarter of the IPO backlog, necessitating close monitoring of market dynamics.
See More
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
See More
February IPO Market Review and Outlook
- Strong Fundraising: In February, 13 IPOs raised a total of $4.4 billion, surpassing the historical average over the past decade, indicating sustained investor interest in new listings despite market volatility.
- Market Volatility Impact: Although IPO activity was robust at the beginning of February, concerns over AI disruption led to a sell-off in tech stocks mid-month, resulting in price cuts and postponements for some high-profile IPOs, reflecting market uncertainty.
- Return Performance: The average return for IPOs this month was 22%, with those raising over $100 million achieving an impressive 28%, suggesting that investors remain optimistic about growth potential in the biotech and consumer sectors.
- Optimistic Future Outlook: Despite a decline in new filing activity, stabilizing market conditions are expected to encourage a gradual increase in IPO issuance in March, particularly given the strong performance of recent listings.
See More
Key Wall Street Rating Changes on Monday
- Morgan Stanley Bullish on Nvidia: Morgan Stanley names Nvidia a top pick, viewing the current stock price at 18x CY27 EPS as an attractive entry point, expecting market concerns about growth durability to shift to enthusiasm in the coming months.
- Barclays Downgrades Blue Owl: Barclays downgrades Blue Owl from overweight to equal weight, citing overly high market estimates and suggesting that the stock is now closer to fairly priced based on earnings growth potential.
- Piper Sandler Upgrades CrowdStrike: Piper Sandler upgrades CrowdStrike from neutral to overweight, maintaining a $520 price target, arguing that the market's bearish sentiment driven by AI narratives is overdone for a leading security platform with a strong track record.
- Goldman Sachs Upgrades Dutch Bros: Goldman Sachs upgrades Dutch Bros from neutral to buy, asserting that the market is underestimating the coffee chain's fundamental strength and competitive positioning amid a challenging coffee landscape.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Dynamics Overview: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: For those considering buying NTRP stock, analysts' opinions may provide crucial market insights, aiding in more informed investment choices.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst rating changes, and investors should monitor these shifts to seize market opportunities.
See More
U.S. IPO Market Set for Significant Wave in 2026
- Surge in IPO Proceeds: Goldman Sachs projects that U.S. IPO proceeds will reach a record $160 billion in 2026, quadrupling from 2025, indicating strong economic recovery and robust equity markets.
- Doubling of IPO Count: The number of IPOs is expected to double to 120 in 2026, driven by a recovering economy, rising equity prices, and favorable financial conditions, with software and healthcare sectors leading the charge.
- Large Company Listings: Goldman Sachs notes that 2026 IPOs will be dominated by large private company listings, with proceeds estimated between $80 billion and $200 billion, although recent selloffs in software stocks highlight valuation risks.
- Signs of Market Activity: Approximately $5 billion has already been raised through IPOs in 2026, including notable companies like AI equipment manufacturer Forgent Power and biopharmaceutical firm Eikon Therapeutics, reflecting a strong market rebound.
See More
US IPO Market Set for Major Rebound in 2026
- IPO Revenue Forecast: Goldman Sachs analysts predict that US IPO proceeds will reach a record $160 billion in 2026, quadrupling from 2025, reflecting strong demand for major companies, particularly with anticipated listings from SpaceX and OpenAI.
- Surge in IPO Numbers: The number of IPOs is expected to double to 120 in 2026, driven by economic growth, rising equity prices, and improved financial conditions, indicating strong market interest and confidence in new public offerings.
- Industry Dominance: Software and healthcare firms are set to dominate the IPO pipeline by volume, while late-stage tech and AI companies are expected to drive proceeds, showcasing ongoing investor focus and trust in technological innovation.
- Market Risk Warning: Despite the optimistic outlook, Goldman warns that ongoing volatility in software stocks and lack of corporate confidence could impact the IPO market, particularly as the software sector accounts for about a quarter of the IPO backlog, necessitating close monitoring of market dynamics.
See More
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
See More
